GLP-1 Market
LLY $1306.69 ▲ +2.8% NVO $39.43 ▲ +0.9% PFE $30.42 ▲ +1.9% VKTX $25.83 ▼ -2.1% KLRA $13.27 ▲ +2.7% GPCR $21.93 ▼ -0.4% RHHBY $59.62 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

PCS499

PCS499

Company
Processa Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 23, 2026

Trial details
  • Completed NCT NCT03698864

    A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

    Not yet reported Processa Pharmaceuticals 12 participants Est. completion 2020-02-25 2 sites Stand-alone
    Other conditions: Necrobiosis Lipoidica
    View official trial listing →
  • Completed NCT NCT03836222

    Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects

    Not yet reported Processa Pharmaceuticals 18 participants Est. completion 2018-06-04 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT04800562

    A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

    Not yet reported Processa Pharmaceuticals 4 participants Est. completion 2023-04-14 4 sites Stand-alone
    Other conditions: Necrobiosis Lipoidica
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: PCS499, deuterated pentoxifylline analog

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.